Clesrovimab, a new RSV shot approved by the FDA, is administered in a single 105 mg dose for all infants. Clinical trials revealed concerning side effects, including a 50% higher risk of death among those receiving the shot compared to a placebo group. Results from 2,409 infants indicated that three deaths occurred among those receiving clesrovimab versus one in the placebo group. Additionally, there was a 350% higher risk of upper respiratory tract infections and a 63% higher risk of lower respiratory tract infections among infants given the shot.
Among the babies given clesrovimab, there was a 50% higher risk of death compared to those in the placebo group. That's three deaths in the shot group versus one in the placebo.
The risk of respiratory tract infections (RTIs) also soared - According to the data, infants who received the shot had a 350% higher risk of getting an upper RTI and a 63% higher risk of lower RTIs.
Collection
[
|
...
]